von Allmen D. Pediatric Crohn's Disease. Clin Colon Rectal Surg. 2018 Mar. 31 (2):80-88. [Medline].
LOCKHART-MUMMERY HE, MORSON BC. Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut. 1960 Jun. 1:87-105. [Medline].
Aufses AH Jr. The history of Crohn's disease. Surg Clin North Am. 2001 Feb. 81 (1):1-11, vii. [Medline].
Lemberg DA, Clarkson CM, Bohane TD, Day AS. Role of esophagogastroduodenoscopy in the initial assessment of children with inflammatory bowel disease. J Gastroenterol Hepatol. 2005 Nov. 20 (11):1696-700. [Medline].
Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol. 2003 Nov-Dec. 37 (5):358-67. [Medline].
Church JM. Molecular genetics and Crohn's disease. Surg Clin North Am. 2001 Feb. 81 (1):31-8, vii-viii. [Medline].
Van Heel DA, McGovern DP, Jewell DP. Crohn's disease: genetic susceptibility, bacteria, and innate immunity. Lancet. 2001 Jun 16. 357 (9272):1902-4. [Medline].
Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut. 1992 Jun. 33 (6):779-82. [Medline].
D'Souza S, Levy E, Mack D, Israel D, Lambrette P, Ghadirian P, et al. Dietary patterns and risk for Crohn's disease in children. Inflamm Bowel Dis. 2008 Mar. 14 (3):367-73. [Medline].
Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med. 2001 Mar. 155 (3):354-9. [Medline].
Reif S, Lavy A, Keter D, Broide E, Niv Y, Halak A, et al. Appendectomy is more frequent but not a risk factor in Crohn's disease while being protective in ulcerative colitis: a comparison of surgical procedures in inflammatory bowel disease. Am J Gastroenterol. 2001 Mar. 96 (3):829-32. [Medline].
Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008 Aug. 103 (8):1998-2006. [Medline].
Loftus CG, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007 Mar. 13 (3):254-61. [Medline].
Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007 Dec. 5 (12):1424-9. [Medline].
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr. 96 (4):1116-22. [Medline].
Tromm A, May D, Almus E, Voigt E, Greving I, Schwegler U, et al. Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol. 2001 Feb. 39 (2):137-44. [Medline].
Paerregaard A, Uldall Urne F. Anthropometry at the time of diagnosis in Danish children with inflammatory bowel disease. Acta Paediatr. 2005 Nov. 94 (11):1682-3. [Medline].
Pallotta N, Civitelli F, Di Nardo G, Vincoli G, Aloi M, Viola F, et al. Small intestine contrast ultrasonography in pediatric Crohn's disease. J Pediatr. 2013 Sep. 163 (3):778-84.e1. [Medline].
Pilleul F, Godefroy C, Yzebe-Beziat D, Dugougeat-Pilleul F, Lachaux A, Valette PJ. Magnetic resonance imaging in Crohn's disease. Gastroenterol Clin Biol. 2005 Aug-Sep. 29 (8-9):803-8. [Medline].
Florie J, Horsthuis K, Hommes DW, Nio CY, Reitsma JB, van Deventer SJ, et al. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin Gastroenterol Hepatol. 2005 Dec. 3 (12):1221-8. [Medline].
Absah I, Bruining DH, Matsumoto JM, Weisbrod AJ, Fletcher JG, Fidler JL, et al. MR enterography in pediatric inflammatory bowel disease: retrospective assessment of patient tolerance, image quality, and initial performance estimates. AJR Am J Roentgenol. 2012 Sep. 199 (3):W367-75. [Medline].
[Guideline] Bruining DH, Zimmermann EM, Loftus EV Jr, et al, for the Society of Abdominal Radiology Crohn’s Disease-Focused Panel. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn's disease. Gastroenterology. 2018 Mar. 154 (4):1172-94. [Medline].
Toh JW, Stewart P, Rickard MJ, Leong R, Wang N, Young CJ. Indications and surgical options for small bowel, large bowel and perianal Crohn's disease. World J Gastroenterol. 2016 Oct 28. 22 (40):8892-8904. [Medline]. [Full Text].
[Guideline] Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014 Oct. 8 (10):1179-207. [Medline]. [Full Text].
CHANOINE F. [Treatment of Crohn's disease with salicylate derivatives]. Arch Mal Appar Dig Mal Nutr. 1961 Nov. 50:1212-7. [Medline].
Grand RJ, Ramakrishna J, Calenda KA. Therapeutic strategies for pediatric Crohn disease. Clin Invest Med. 1996 Oct. 19 (5):373-80. [Medline].
Knutson D, Greenberg G, Cronau H. Management of Crohn's disease--a practical approach. Am Fam Physician. 2003 Aug 15. 68 (4):707-14. [Medline].
Ginsberg AL. Topical salicylate therapy (4-ASA and 5-ASA enemas). Gastroenterol Clin North Am. 1989 Mar. 18 (1):35-42. [Medline].
Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Apr 16. CD006792. [Medline].
Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther. 2007 Aug 1. 26 (3):313-29. [Medline].
Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995 Jun. 108 (6):1617-21. [Medline].
Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980 Aug. 79(2):357-65. [Medline].
Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980 May 1. 302 (18):981-7. [Medline].
Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Jan 21. CD000067. [Medline].
Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008 Sep 28. 14 (36):5512-8. [Medline]. [Full Text].
Brynskov J, Freund L, Rasmussen SN, Lauritsen K, de Muckadell OS, Williams N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med. 1989 Sep 28. 321 (13):845-50. [Medline].
Chermesh I, Tamir A, Lachter J, Eliakim R. Intravenous cyclosporine for inflammatory bowel disease--safe and effective. Hepatogastroenterology. 2007 Oct-Nov. 54 (79):2003-6. [Medline].
Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998 Oct. 93 (10):1860-6. [Medline].
Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008 Jan. 14 (1):7-12. [Medline].
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol. 2006 May. 101 (5):1048-56. [Medline].
Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis. 2007 Mar. 13 (3):245-53. [Medline].
Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol. 2009 Apr 7. 15 (13):1594-9. [Medline].
Palaniappan S, Ford AC, Greer D, Everett SM, Chalmers DM, Axon AT, et al. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007 Dec. 13 (12):1488-92. [Medline].
D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999 May. 116 (5):1029-34. [Medline].
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6. 340 (18):1398-405. [Medline].
Hoffman I, Vermeire S, Van Assche G, Rutgeerts P. Infliximab for pediatric Crohn's disease. Drugs Today (Barc). 2008 Aug. 44 (8):615-28. [Medline].
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009 Apr. 58 (4):492-500. [Medline].
Gasparetto M, Corradin S, Vallortigara F, Cananzi M, Guariso G. Infliximab and pediatric stricturing Crohn's disease: a possible alternative to surgery? Experience of seven cases. Acta Gastroenterol Belg. 2012 Mar. 75 (1):58-60. [Medline].
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May. 120 (6):1330-8. [Medline].
Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999 Dec. 117 (6):1278-87. [Medline].
Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, et al. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut. 1997 Mar. 40 (3):320-7. [Medline].
Song HK, Buzby GP. Nutritional support for Crohn's disease. Surg Clin North Am. 2001 Feb. 81 (1):103-15, viii. [Medline].
Gavin J, Anderson CE, Bremner AR, Beattie RM. Energy intakes of children with Crohn's disease treated with enteral nutrition as primary therapy. J Hum Nutr Diet. 2005 Oct. 18 (5):337-42. [Medline].
Stewart D. Surgical care of the pediatric Crohn's disease patient. Semin Pediatr Surg. 2017 Dec. 26 (6):373-378. [Medline].
Kim S. Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management. Pediatr Gastroenterol Hepatol Nutr. 2017 Mar. 20 (1):14-21. [Medline]. [Full Text].
Blackburn SC, Wiskin AE, Barnes C, Dick K, Afzal NA, Griffiths DM, et al. Surgery for children with Crohn's disease: indications, complications and outcome. Arch Dis Child. 2014 May. 99 (5):420-6. [Medline].
Markowitz J, Markowitz JE, Bousvaros A, Crandall W, Faubion W, Kirschner BS, et al. Workshop report: prevention of postoperative recurrence in Crohn's disease. J Pediatr Gastroenterol Nutr. 2005 Aug. 41 (2):145-51. [Medline].
Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion. 1989. 42 (4):224-32. [Medline].
Alós R, Hinojosa J. Timing of surgery in Crohn's disease: a key issue in the management. World J Gastroenterol. 2008 Sep 28. 14 (36):5532-9. [Medline].
Simillis C, Yamamoto T, Reese GE, Umegae S, Matsumoto K, Darzi AW, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. Am J Gastroenterol. 2008 Jan. 103 (1):196-205. [Medline].
Shen B. Managing medical complications and recurrence after surgery for Crohn's disease. Curr Gastroenterol Rep. 2008 Dec. 10 (6):606-11. [Medline].
Romeo E, Jasonni V, Caldaro T, Barabino A, Mattioli G, Vignola S, et al. Strictureplasty and intestinal resection: different options in complicated pediatric-onset Crohn disease. J Pediatr Surg. 2012 May. 47 (5):944-8. [Medline].
Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007 Nov. 50 (11):1968-86. [Medline].
Couckuyt H, Gevers AM, Coremans G, Hiele M, Rutgeerts P. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut. 1995 Apr. 36 (4):577-80. [Medline].
Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol. 2001 May-Jun. 32 (5):409-12. [Medline].
Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002 Jul. 184 (1):45-51. [Medline].
Kamm MA, Ng SC. Perianal fistulizing Crohn's disease: a call to action. Clin Gastroenterol Hepatol. 2008 Jan. 6 (1):7-10. [Medline].
Guidi L, Ratto C, Semeraro S, Roberto I, De Vitis I, Papa A, et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol. 2008 Jun. 12 (2):111-7. [Medline].
Bode M, Eder S, Schürmann G. [Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?]. Z Gastroenterol. 2008 Dec. 46 (12):1376-83. [Medline].
Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum. 2002 Jun. 45 (6):771-5. [Medline].
[Guideline] Amil-Dias J, Kolacek S, Turner D, Pærregaard A, Rintala R, Afzal NA, et al. Surgical Management of Crohn Disease in Children: Guidelines From the Paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2017 May. 64 (5):818-835. [Medline]. [Full Text].
Liu CD, Rolandelli R, Ashley SW, Evans B, Shin M, McFadden DW. Laparoscopic surgery for inflammatory bowel disease. Am Surg. 1995 Dec. 61 (12):1054-6. [Medline].
Sardinha TC, Wexner SD. Laparoscopy for inflammatory bowel disease: pros and cons. World J Surg. 1998 Apr. 22 (4):370-4. [Medline].
Georgeson KE, Cohen RD, Hebra A, Jona JZ, Powell DM, Rothenberg SS, et al. Primary laparoscopic-assisted endorectal colon pull-through for Hirschsprung's disease: a new gold standard. Ann Surg. 1999 May. 229 (5):678-82; discussion 682-3. [Medline].
Lowney JK, Dietz DW, Birnbaum EH, Kodner IJ, Mutch MG, Fleshman JW. Is there any difference in recurrence rates in laparoscopic ileocolic resection for Crohn's disease compared with conventional surgery? A long-term, follow-up study. Dis Colon Rectum. 2006 Jan. 49 (1):58-63. [Medline].
Chen HH, Wexner SD, Iroatulam AJ, Pikarsky AJ, Alabaz O, Nogueras JJ, et al. Laparoscopic colectomy compares favorably with colectomy by laparotomy for reduction of postoperative ileus. Dis Colon Rectum. 2000 Jan. 43 (1):61-5. [Medline].
Eshuis EJ, Polle SW, Slors JF, Hommes DW, Sprangers MA, Gouma DJ, et al. Long-term surgical recurrence, morbidity, quality of life, and body image of laparoscopic-assisted vs. open ileocolic resection for Crohn's disease: a comparative study. Dis Colon Rectum. 2008 Jun. 51 (6):858-67. [Medline].
Laituri CA, Fraser JD, Garey CL, Aguayo P, Sharp SW, Ostlie DJ, et al. Laparoscopic ileocecectomy in pediatric patients with Crohn's disease. J Laparoendosc Adv Surg Tech A. 2011 Mar. 21 (2):193-5. [Medline].
Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MA, Bossuyt PM, van Milligen de Wit AW, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg. 2008 Aug 22. 8:15. [Medline].
de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, et al. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial. Gut. 2019 Oct. 68 (10):1774-1780. [Medline].
Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2020 Oct. 5 (10):900-907. [Medline].